DBG
REGN icon

De Burlo Group’s Regeneron Pharmaceuticals REGN Stock Holding History

De Burlo Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,390
Closed -$8.82M – 82
2024
Q3 		$8.82M Sell
8,390
-300
-3% -$334K 1.09% 26
2024
Q2 		$9.13M Buy
8,690
+600
+7% +$582K 1.23% 26
2024
Q1 		$7.79M Buy
+8,090
New +$7.69M 1.03% 28
2023
Q2 		– Sell
-20,590
Closed -$16.9M – 91
2023
Q1 		$16.9M Buy
20,590
+8,900
+76% +$6.71M 3.3% 7
2022
Q4 		$8.43M Hold
11,690
– – 1.88% 21
2022
Q3 		$8.05M Buy
+11,690
New +$7.36M 1.92% 18
2022
Q2 		– Sell
-26,190
Closed -$18.3M – 178
2022
Q1 		$18.3M Buy
26,190
+13,600
+108% +$8.6M 3.41% 9
2021
Q4 		$7.95M Sell
12,590
-6,610
-34% -$4.06M 1.15% 31
2021
Q3 		$11.6M Buy
+19,200
New +$11.9M 1.88% 18
2020
Q4 		– Sell
-4,750
Closed -$2.66M – 94
2020
Q3 		$2.66M Buy
+4,750
New +$2.88M 0.48% 46
2019
Q2 		– Sell
-18,200
Closed -$7.47M – 94
2019
Q1 		$7.47M Buy
+18,200
New +$7.49M 1.51% 29
2016
Q1 		– Sell
-11,550
Closed -$6.27M – 100
2015
Q4 		$6.27M Buy
11,550
+1,500
+15% +$813K 1.48% 32
2015
Q3 		$4.67M Buy
+10,050
New +$5.4M 1.1% 44

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

De Burlo Group's REGN Position: Q4 2024 in Review

De Burlo Group sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 8,390 shares — an estimated $8.82M sold.

De Burlo Group first reported a position in REGN in Q3 2015 and held it in 13 quarters. The position peaked at $18.3M in Q1 2022. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

  • De Burlo Group reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • De Burlo Group sold 8,390 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $8.82M.
  • De Burlo Group first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 13 quarters.
  • De Burlo Group's Regeneron Pharmaceuticals position peaked at $18.3M in Q1 2022.
  • 1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on De Burlo Group's 13F filing for Q4 2024, filed 14 Feb 2025.